Resources 
Product Resource
Learning
We Are Pleased to Announce: Global Commercial Licensing Rights for Jurkat E6.1, CHO-K1, and HEK293 Cell Lines Officially Secured.
ExploreArticles
CaSR: The Calcium Homeostasis Sentinel and a Core GPCR Target for Metabolic and Kidney Disease Research
Reqbio offers three CaSR cell models spanning NFAT luciferase reporter and HTRF IP-One assay platforms, with both the broadly used HEK293 host. Together, these models provide drug discovery researchers with a precise, flexible, and cross-validatable set of evaluation tools. Through its cell engineering capabilities and high-precision gene-editing platform, Reqbio continues to provide drug screening cell models covering GPCRs, immunotherapy targets, kinases, and other target classes, together with high-quality cell-based bioassay services.
PAC1R Target: A Core GPCR and Cell Models for Neuromodulation, Pain, and Neuroprotection
With its extreme selectivity for PACAP, precise expression in the nervous system, and diverse downstream signaling network, PAC1R has become a highly attractive GPCR target in neuroscience drug development. From migraine to neuropathic pain and from stroke to neurodegenerative diseases, both PAC1R agonist and antagonist pathways have shown clear prospects for translation. The four PAC1R cell models launched by Reqbio—covering three major assay formats, namely the CRE-Luc reporter gene, HTRF cAMP quantification, and β-arrestin recruitment, together with HEK293 and CHO host backgrounds—provide drug developers worldwide with a complete, flexible, and reliable combination of evaluation tools.
IL-33: A Multifaceted Inflammatory Alarmin and Cell Models for Drug Screening
The IL-33/ST2 axis links tissue damage to immune responses, and its translational potential has become clearer as programs such as tozorakimab and astegolimab have advanced clinically. Across COPD, atopic dermatitis, asthma, and combination cancer immunotherapy, the pathway has broad therapeutic potential. Reqbio’s adherent and suspension IL-33 effector reporter cell models combine sensitive functional readouts with flexible assay formats for drug discovery and development. Using functional cell engineering and precision gene-editing platforms, Reqbio provides drug-testing cell models spanning GPCR, immuno-oncology, kinase, and other target classes, together with cell-based bioactivity assay services.
TRKA Target: A Dual Engine Bridging Neural Regulation and Pan-Cancer Therapy
TRKA is a key therapeutic target with dual roles in neural development and pan-cancer progression. As both the core receptor in the NGF pain signaling pathway and a major oncogenic driver in NTRK fusion-positive tumors, TRKA has become a focal point in modern drug discovery.
TRKA Cell Models – Empowering Dual-Target Drug Discovery in Neuroscience and Oncology
Stable TRKA reporter gene cells and CHO-K1 cell lines for agonist/inhibitor screening and pathway analysis.Reqbio provides NGF/hTRKA and NGF/Canine TRKA reporter gene cells as well as TRKA CHO-K1 stable cell lines for TRKA agonist/inhibitor screening and mechanism studies.
LTBR Cell Models – Reporter Cell Lines & CHO-K1 Cell Lines | Reqbio
LTBR activation induces TLS formation by recruiting T and B cells via chemokines (CXCL13, CCL19), thereby enhancing anti-tumor immunity. However, aberrant LTBR activation can also drive immunosuppressive macrophage polarization and promote tumor progression, giving LTBR a dual functional role in immuno-oncology. Reqbio offers an LTBR Effector Reporter Cell Line and an LTBR CHO-K1 Stable Cell Line for LTBR agonist screening and mechanistic studies. Both models have been validated by dose–response assays and ar
